港股異動 | 中集安瑞科(3899.HK)反彈超7% 投行看好今年業績復甦
格隆匯3月26日丨中集安瑞科(3899.HK)大幅反彈7.39%,報5.52港元,總市值111億港元。該股此前創階段新高後3日回撤20%。中集安瑞科日前公佈,2020年公司收入同比下降10.6%至122.9億元,歸母淨利潤同比下降37.2%至5.8億元。興業證券點評稱,業績稍低於預期,後續將逐步復甦。維持公司“買入”評級,目標價從5.19港元上升至6.30港元;中金看好天然氣長期增長前景,公司在手訂單相對充足,21年有望恢復性增長;國泰君安期待公司2021年的強勁反彈,上調至“買入”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.